1 completed, 1 terminated. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow VEGF inhibitor PTC299: new trials by email Literature Review of VEGF inhibitor PTC299 trials Research Report on VEGF inhibitor PTC299
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors VEGF inhibitor PTC299 - Brain and Central Nervous System Tumors | Phase 1 | Completed | Pediatric Brain Tumor Consortium | 28 | 2010-11-01 | 2015-05-04 |
| PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma VEGF inhibitor PTC299, gene expression analysis, polymerase chain reaction - Kaposi's Sarcoma | Phase 1 / Phase 2 | Terminated | AIDS Malignancy Consortium | 17 | 2008-09-01 | 2018-06-06 |
AIDS-related Kaposi sarcoma (1) · Astrocytoma (1) · Central Nervous System Neoplasms (1) · Familial ependymoma (1) · HIV Infections (1) · Medulloblastoma (1) · Meningioma (1) · Oligodendroglioma (1) · Optic Nerve Glioma (1) · Sarcoma, Kaposi (1) · Spinal Cord Neoplasms (1)
AIDS Malignancy Consortium (1) · Pediatric Brain Tumor Consortium (1)
United States (2)
Roger J. Packer, MD (1) · Susan E. Krown, MD (1)
U01CA081457 (1), U01CA121947 (1)